Original Article
Elevated serum CD26 level is associated with metastasis and post-operation survival in pancreatic cancer patients
Abstract
Background: It has been proved that soluble CD26 (sCD26) has a close relationship with several types of cancers, while its level in pancreatic cancer has not been well established.
Methods: In this study, enzyme-linked immunosorbent assay (ELISA) was applied to test the serum concentration of sCD26 in a total of 148 patients with different pancreatic diseases, including 92 pancreatic ductal adenocarcinoma (PDAC) patients. The correlation between sCD26 level and the clinicopathological features as well as post-operation survival of PDAC patients was also analyzed.
Results: In this cohort, the average sCD26 concentration in healthy donors was 361.30±154.64 µg/L, while it varied in different types of pancreatic diseases. The preoperative sCD26 concentration of PDAC patients was 426.36±207.62 µg/L, which was higher than that in healthy donors (P=0.048) and closely related with tumor location, size, distant metastasis, tumor stage and post-operation survival time. But after operation, the serum concentration decreased to 243.44±113.90 µg/L in PDAC patients.
Conclusions: The findings of this study have unveiled the concentrations of sCD26 in pancreatic diseases, and correlations between increased sCD26 level and favorable clinicopathological features as well as post-operation survival in PDAC patients were also detected.
Methods: In this study, enzyme-linked immunosorbent assay (ELISA) was applied to test the serum concentration of sCD26 in a total of 148 patients with different pancreatic diseases, including 92 pancreatic ductal adenocarcinoma (PDAC) patients. The correlation between sCD26 level and the clinicopathological features as well as post-operation survival of PDAC patients was also analyzed.
Results: In this cohort, the average sCD26 concentration in healthy donors was 361.30±154.64 µg/L, while it varied in different types of pancreatic diseases. The preoperative sCD26 concentration of PDAC patients was 426.36±207.62 µg/L, which was higher than that in healthy donors (P=0.048) and closely related with tumor location, size, distant metastasis, tumor stage and post-operation survival time. But after operation, the serum concentration decreased to 243.44±113.90 µg/L in PDAC patients.
Conclusions: The findings of this study have unveiled the concentrations of sCD26 in pancreatic diseases, and correlations between increased sCD26 level and favorable clinicopathological features as well as post-operation survival in PDAC patients were also detected.
